InMode Eyes $95 Million Q2 Revenue as Strategic Review Continues

The company, which specializes in radio-frequency medical devices for dermatology and plastic surgery, confirmed that its final figures remain subject to adjustment before the market opens on August 5. While the preliminary performance indicators provide a snapshot of the quarter, InMode has opted to bypass the traditional earnings conference call and investor meetings. This silence stems from the ongoing work of a Special Committee currently reviewing strategic proposals for the organization. By reiterating its annual revenue targets, management signals stability even as the firm navigates a period of internal assessment regarding its future direction.